Cardiorenal syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate-Editor(s)-in-Chief: Muzamil Akhtar [2]; Yazan Daaboul; Rim Halaby; Dina Elantably, MD, MSc[3]

Overview

Cardiorenal syndrome (CRS) is an umbrella term for disorders of the heart and kidneys in which acute or chronic dysfunction of one organ induces acute or chronic dysfunction of the other. The modern conception, codified by the Acute Dialysis Quality Initiative (ADQI) and the American Heart Association, frames CRS as a bidirectional spectrum driven by overlapping hemodynamic, neurohormonal, and inflammatory mechanisms rather than by "pump failure" alone. Renal dysfunction is present in roughly 30–50% of patients with heart failure (HF) and is one of the strongest independent predictors of mortality across the ejection-fraction spectrum.

The central contemporary insight is that venous congestion — not low cardiac output — is the dominant driver of worsening renal function in most patients with acute HF, which reframes therapy around effective decongestion. The practical challenge remains distinguishing a benign, hemodynamically mediated rise in creatinine during decongestion (which does not worsen prognosis when congestion is relieved) from true tubular injury, and delivering guideline-directed medical therapy (GDMT) despite fluctuating renal function.

Classification

CRS is subdivided into five ADQI types based on acuity (acute vs. chronic), the primary organ initiating the insult (cardiorenal vs. renocardiac), and the presence of a systemic process affecting both organs.

Type	Designation	Initiating event → Consequence
Type 1	Acute cardiorenal	Acute HF / acute decompensation → acute kidney injury (AKI)
Type 2	Chronic cardiorenal	Chronic HF → progressive CKD
Type 3	Acute renocardiac	AKI → acute cardiac dysfunction (arrhythmia, ischemia, acute HF)
Type 4	Chronic renocardiac	CKD → chronic cardiac dysfunction / uremic cardiomyopathy
Type 5	Secondary	Systemic disorder (sepsis, diabetes, amyloidosis, SLE, sarcoidosis) → simultaneous cardiac + renal dysfunction

Caveats to the classification: The ADQI scheme is useful for structuring bedside reasoning but has recognized limitations: - Phenotypes overlap and transition over time (e.g., ~14–20% of chronic CRS patients develop a superimposed acute CRS episode), and identifying the initial insult is often impossible in practice. - Epidemiologic studies have not cleanly separated type 2 from type 4, because chronic HF and CKD are each strong risk factors for the other. - Proposed refinements add volume status (hyper- vs. hypovolemia) and valvular vs. nonvalvular status, but these await widespread validation.

Pathophysiology

CRS arises from the convergence of hemodynamic, neurohormonal, and inflammatory pathways that create a self-perpetuating cycle of congestion and organ injury.

Venous congestion is the predominant hemodynamic driver. The older cardiocentric model attributed CRS to reduced forward flow and prerenal hypoperfusion, but this fails to explain reduced GFR in patients with preserved ejection fraction and normal/elevated blood pressure. The kidneys receive ~25% of cardiac output as a low-resistance circuit, and glomerular filtration depends on the gradient between arterial driving pressure and renal venous outflow pressure. Elevated central venous pressure (CVP) raises renal venous and interstitial pressure, narrows this gradient, triggers tubular collapse, and reduces GFR. Right atrial pressure is often the only hemodynamic parameter independently associated with baseline renal dysfunction. Congestion also extends to the hepatic, splenic, and mesenteric venous beds, overwhelming lymphatic drainage and raising intra-abdominal pressure.

Neurohormonal activation. Reduced effective arterial volume activates the renin–angiotensin–aldosterone system (RAAS), the sympathetic nervous system, and arginine vasopressin, driving sodium/water retention, efferent arteriolar vasoconstriction (which transiently preserves filtration fraction), and systemic vasoconstriction. These responses override the vasodilatory/natriuretic effects of natriuretic peptides, nitric oxide, and prostaglandins. In severe decompensation with very high renal venous pressure, the compensatory rise in filtration fraction is lost and GFR falls. This same physiology explains why RAAS inhibitors cause a predictable creatinine rise that reflects reduced intraglomerular pressure rather than injury — and becomes true worsening only when mean arterial pressure falls below renal autoregulatory capacity.

Inflammation and oxidative stress. Chronic HF and CKD are proinflammatory states; gut congestion and endothelial dysfunction amplify cytokine release, while angiotensin II–driven reactive oxygen species promote tubular injury, fibrosis, and progressive cardiomyopathy.

Mechanisms by subtype: - Type 1: acute fall in cardiac output ± venous congestion → reduced renal perfusion pressure and intrarenal mechanisms → AKI. - Type 3: AKI → volume/pressure overload, uremia, electrolyte disturbance, acidemia, and direct neurohormonal/oxidative myocardial effects → acute cardiac dysfunction. - Types 2 and 4: chronic cross-talk via sustained neurohormonal activation, uremic toxins, pressure/volume overload, anemia, and vascular calcification. - Type 5: a systemic insult (e.g., sepsis) injures both organs in parallel.

The bidirectional relationship between the heart and kidneys in the pathophysiology of the cardiorenal syndrome.

The complex pathophysiological mechanisms involved in the cardiorenal syndrome.

Epidemiology and Demographics

- Renal dysfunction in HF is the rule, not the exception: moderate-to-severe renal impairment affects ~30–50% of HF patients overall. - In the ADHERE registry of acute decompensated HF, only ~9% of patients had normal renal function; ~91% had an eGFR <90 mL/min/1.73 m². - AKI complicates ~24–45% of acute decompensated HF admissions, and up to ~40% of AHF hospitalizations manifest a type 1 CRS phenotype. - Worsening renal function (WRF) occurs in ~23% of HF patients, is common across all ejection-fraction categories, and is most frequent in HFpEF (~42% vs. ~35% in HFmrEF/HFrEF over one year). - Among patients with CKD/ESKD, cardiovascular disease dominates: roughly half of deaths in CKD are cardiovascular in origin.

Risk Factors

Validated predictors of worsening renal function in HF include: - Baseline CKD / reduced eGFR (the strongest predictor) - Diabetes mellitus - Hypertension (including admission systolic BP >160 mmHg) - Prior HF / prior HF hospitalization - Older age - Higher baseline diuretic requirement - Elevated admission creatinine (≥1.5 mg/dL)

Diagnosis

CRS is a clinical diagnosis integrating evidence of concurrent cardiac and renal dysfunction with assessment of volume status and congestion. The key diagnostic task is to characterize the congestion phenotype and distinguish hemodynamic (functional, reversible) changes in filtration from intrinsic tubular injury.

Laboratory Findings

- Serum creatinine and functional biomarkers: Serum creatinine remains the standard but lags injury by 48–72 hours, is insensitive to early GFR change, and is confounded by age, sex, muscle mass, and drugs. Cystatin C is freely filtered, reabsorbed, not secreted, and independent of muscle mass; it correlates with GFR and carries independent prognostic value for mortality and rehospitalization in HF. - Tubular injury biomarkers: NGAL (neutrophil gelatinase-associated lipocalin) is a well-studied tubular marker predicting AKI and dialysis, though it is not widely approved for routine clinical use in the United States and can be nonspecific. The TIMP-2 × IGFBP7 cell-cycle-arrest panel is FDA-cleared in the U.S. for AKI risk. Urine microscopy (renal tubular epithelial cells, granular casts) is an inexpensive, high-value tool to distinguish intrinsic AKI from functional creatinine change.

Imaging and Congestion Assessment

- Echocardiography: Estimates filling pressures (E/E′ >15 ≈ pulmonary capillary wedge pressure ≥18 mmHg), RV size/function, and pulmonary pressures. - Venous Excess Ultrasound (VExUS): Grades systemic venous congestion using IVC diameter plus hepatic, portal, and intrarenal vein Doppler. VExUS grade correlates strongly with invasively measured right atrial pressure and predicts cardiorenal AKI, HF readmission, and mortality. - Intrarenal venous flow patterns: A continuous pattern indicates low right atrial pressure and favorable prognosis (>95% 1-year survival), whereas discontinuous/monophasic patterns indicate high RA pressure and poor prognosis (<40% 1-year survival). - Lung ultrasound: Assessment of B-lines complements venous Doppler in multimodality, imaging-guided decongestion. - Renal ultrasonography: Evaluates kidney size, cortical thickness, and echogenicity to establish chronicity and distinguish AKI from CKD.

Natural History, Complications, and Prognosis

Renal dysfunction is among the most powerful independent prognostic markers in HF. CKD confers roughly a doubling of mortality (OR 2.34), and worsening renal function confers an independent HR of ~1.95. - Prognosis tracks the magnitude of renal decline and the congestion phenotype. Acute CRS (types 1/3) carries the highest mortality (HR ~3.1 vs. CKD without CRS). - The prognostic meaning of a creatinine rise depends on congestion status. A modest creatinine increase during effective decongestion, in a patient rendered euvolemic, is not associated with worse outcomes; a rise with persistent congestion and poor diuretic response is ominous. - After an HF hospitalization, a lower discharge eGFR predicts a steep gradient of downstream dialysis, ESKD, and AKI risk.

Medical Therapy

Management centers on effective, sustained decongestion while initiating and protecting disease-modifying GDMT and avoiding nephrotoxins. Outcomes improve when congestion is relieved.

Decongestion and Loop Diuretics

- IV loop diuretics for patients admitted with fluid overload is a Class I recommendation. - Dose adequately from the start. Per the DOSE trial, initial IV loop dosing of ~2.5× the home oral dose improves decongestion endpoints; bolus and continuous infusion produce equivalent diuresis and safety. In diuretic-naïve patients, 20–40 mg IV furosemide-equivalents is a reasonable start. Low-dose diuretics are frequently inadequate in CRS, where diuretic delivery and tubular responsiveness are impaired. - Assess diuretic response early (spot urine sodium and/or urine output at 2–6 h). A spot urine sodium <50–70 mmol/L or urine output <100–150 mL/h signals inadequate response and the need to escalate.

Sequential Nephron Blockade

When response is inadequate, escalate in a stepped fashion (modeled on CARRESS-HF): double the loop dose up to a ceiling, then add a second agent: - Thiazide/thiazide-like diuretics (e.g., metolazone, chlorothiazide) for distal nephron blockade — monitor for hypokalemia and hyponatremia. - IV acetazolamide: In the ADVOR trial, adding acetazolamide to IV loop diuretics improved decongestion across the full range of renal function. It increased transient WRF without worsening 3-month creatinine or clinical outcomes.

Guideline-Directed Medical Therapy (GDMT)

Start early and protect therapy through minor creatinine fluctuations: - SGLT2 inhibitors (dapagliflozin, empagliflozin) are cardiorenal protective and should be added early during hospitalization. They reduce HF hospitalization and slow eGFR decline independent of diabetes status, and may be initiated down to an eGFR of ~20 mL/min/1.73 m². - RAAS inhibitors / ARNI: Expect and tolerate a transient creatinine rise. An increase in creatinine <50% above baseline (and <3.0 mg/dL) or an eGFR fall <10% (as long as eGFR >25 mL/min/1.73 m²) is acceptable and should not prompt discontinuation. Hold RAAS inhibitors during severe AKI. - Mineralocorticoid receptor antagonists (MRAs): Spironolactone/eplerenone are foundational in HFrEF. In HFmrEF/HFpEF, the nonsteroidal MRA finerenone (FINEARTS-HF) is FDA-approved (as of 2025) and is designated the MRA of choice in HFpEF by the 2026 ACC Expert Consensus. Potassium and eGFR monitoring is strictly required.

Surgery / Procedural Therapy

- In CARRESS-HF, the ultrafiltration arm was stopped early for inferiority (a greater creatinine rise with equivalent weight loss) and carried higher 60-day adverse events; routine ultrafiltration for ADHF is therefore not recommended. Patients with serum creatinine >2.5 mg/dL or requiring solute clearance generally need a clearance-providing RRT modality rather than isolated ultrafiltration. Consider for severe diuretic resistance with adequate kidney function; those with severe intrinsic renal dysfunction may require definitive renal replacement therapy (RRT).

Supportive and Type-Specific Measures

- Low-output/hypoperfused patients (cold-wet): Inotropes (dobutamine, milrinone) and selective vasodilators can augment cardiac index and renal perfusion as a bridge. - Avoid nephrotoxins: Discontinue NSAIDs, aminoglycosides, and limit iodinated contrast. - Primary/Secondary Prevention: Optimal control of hypertension/diabetes, cardiorenal-protective GDMT, sustained euvolemia, and early HF-clinic follow-up (7–14 days) post-discharge to prevent readmission.

High-Yield Clinical Pearls

- Treat congestion, not the creatinine. In most acute CRS, a rising creatinine with persistent congestion calls for more effective decongestion, not diuretic withdrawal. - Right atrial/central venous pressure is the hemodynamic parameter most strongly tied to renal dysfunction. - Check a spot urine sodium 2 hours after the first IV loop dose to gauge response and escalate early rather than waiting for failed daily weights. - Expect a creatinine bump with RAAS inhibitors/ARNI; stay the course within accepted limits (<50% rise, eGFR >25), as this reflects hemodynamics, not intrinsic injury. - VExUS grade 2–3 or a discontinuous intrarenal venous flow pattern flags severe congestion and a poor prognosis, acting as a valuable tool to track the response to decongestion.

Common Pitfalls

- Under-dosing diuretics out of fear of renal injury, leading to persistent congestion — the strongest driver of both renal decline and readmission. - Stopping GDMT (RAAS inhibitor, SGLT2 inhibitor) for a modest, expected creatinine rise, forfeiting long-term cardiorenal protection. - Reflexively adding fluids to a "prerenal" creatinine in a congested patient, which worsens venous congestion. - Jumping to ultrafiltration before an adequate stepped pharmacologic trial (contradicted by the CARRESS-HF trial). - Over-relying on serum creatinine and missing early tubular injury; urine microscopy and overall trajectory are more informative than a single value.